| Targeting TREM2 on tumor-associated macrophages enhances immunotherapy M Binnewies, JL Pollack, J Rudolph, S Dash, M Abushawish, T Lee, ... Cell Reports 37 (3), 2021 | 151 | 2021 |
| Detection of Parkin (PARK2) and DJ1 (PARK7) mutations in early‐onset Parkinson disease: Parkin mutation frequency depends on ethnic origin of patients A Djarmati, K Hedrich, M Svetel, N Schäfer, V Juric, S Vukosavic, ... Human mutation 23 (5), 525-525, 2004 | 114 | 2004 |
| Targeted mutagenesis of the angiogenic protein CCN1 (CYR61): Selective inactivation of integrin α6β1-heparan sulfate proteoglycan coreceptor-mediated cellular functions SJ Leu, N Chen, CC Chen, V Todorovic, T Bai, V Juric, Y Liu, G Yan, ... Journal of Biological Chemistry 279 (42), 44177-44187, 2004 | 86 | 2004 |
| Identification of chemical inhibitors of β-catenin-driven liver tumorigenesis in zebrafish KJ Evason, MT Francisco, V Juric, S Balakrishnan, MP Lopez Pazmino, ... PLoS genetics 11 (7), e1005305, 2015 | 83 | 2015 |
| Fas-mediated apoptosis is regulated by the extracellular matrix protein CCN1 (CYR61) in vitro and in vivo V Juric, CC Chen, LF Lau Molecular and cellular biology 29 (12), 3266-3279, 2009 | 79 | 2009 |
| Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis CA Franzen, CC Chen, V Todorović, V Juric, RI Monzon, LF Lau Molecular Cancer Research 7 (7), 1045-1055, 2009 | 75 | 2009 |
| TNFα-induced apoptosis enabled by CCN1/CYR61: pathways of reactive oxygen species generation and cytochrome c release V Juric, CC Chen, LF Lau PloS one 7 (2), e31303, 2012 | 57 | 2012 |
| Monocytes promote liver carcinogenesis in an oncogene-specific manner V Juric, B Ruffell, KJ Evason, J Hu, L Che, L Wang, X Chen, JM Bishop Journal of hepatology 64 (4), 881-890, 2016 | 14 | 2016 |
| The extracellular matrix protein CCN1 dictates TNFα and FasL cytotoxicity in vivo CC Chen, V Juric, LF Lau Advances in TNF Family Research: Proceedings of the 12th International TNF …, 2011 | 8 | 2011 |
| TREM1 activation of myeloid cells promotes antitumor immunity V Juric, E Mayes, M Binnewies, T Lee, P Canaday, JL Pollack, J Rudolph, ... Science Translational Medicine 15 (711), eadd9990, 2023 | 5 | 2023 |
| Targeted Mutagenesis of the Angiogenic Protein CCN1 (CYR61): SELECTIVE INACTIVATION OF INTEGRIN a6b1-HEPARAN SULFATE PROTEOGLYCAN CORECEPTOR-MEDIATED CELLULAR FUNCTIONS SJ Leu, N Chen, CC Chen, V Todorovic, T Bai, V Juric, Y Liu, G Yan, ... Journal of Biological Chemistry 279 (42), 44177-44187, 2004 | 5 | 2004 |
| Monocyte-dependent liver injury promotes carcinogenesis in an oncogene-specific manner V Juric, B Ruffell, KJ Evason, J Hu, L Che, L Wang, X Chen, JM Bishop J Hepatol, 2015 | 1 | 2015 |
| Anti-MARCO Antibodies and Uses Thereof N Jahchan, M Streuli, X Yang, L Liang, V Sriram, J Pollack, K Mojica, ... US Patent App. 18/068,237, 2024 | | 2024 |
| Anti-MARCO antibodies and uses thereof N Jahchan, M Streuli, X Yang, L Liang, V Sriram, J Pollack, K Mojica, ... US Patent 11,572,407, 2023 | | 2023 |
| Therapeutic targeting of MARCO with PY265 antibody promotes myeloid cell reprogramming and unleashes anti-tumor immunity L Haeggblom, S Dash, Y Vayn, J Rudolph, R Palmer, X Yang, C Juarez, ... Journal for ImmunoTherapy of Cancer 10, A1393-A1393, 2022 | | 2022 |
| 1340 BT7455, a fully synthetic Bicycle tumor-targeted immune cell agonist®, leads to potent EphA2-dependent CD137 agonism and robust anti-tumor efficacy K Hurov, L Luus, J Lahdenranta, P Upadhyaya, H Cohen, C Shah, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | | 2022 |
| Pharmacologic inhibition of HPK1 kinase activity enhances immune cell activation and T cell mediated anti-tumor activity JS Lee, P Toy, G Min-Oo, T Lee, P Salvo, JP Belzile, S Clancy, ... Cancer Research 82 (12_Supplement), 3517-3517, 2022 | | 2022 |
| P02. 11 TREM1 agonist PY159 promotes myeloid cell reprogramming and unleashes anti-tumor immunity V Juric, E Mayes, M Binnewies, P Canaday, T Lee, S Dash, JL Pollack, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 1), 2021 | | 2021 |
| Identification of Chemical Inhibitors of β-Catenin-Driven Liver Tumorigenesis in Zebrafish A Goga, S Kakar, KJ Evason, MT Francisco, V Juric, S Balakrishnan, ... | | 2015 |
| Abstract PR1: Oncogenic driver mutations shape the nature of immune responses in tumors. V Juric, B Ruffell, JM Bishop Cancer Research 73 (1_Supplement), PR1-PR1, 2013 | | 2013 |
